• Dual HER2–VEGFR-2 Targeting in Breast Cancer

  2026-09-17

  The 2026 reference study evaluates Lapatinib and Telatinib as a dual-targeting strategy in HER2-negative MDA-MB-231 triple-negative breast cancer cells. Reduced invadopodia formation, cell proliferation, and two-dimensional tube formation support further phenotype-focused investigation, while the results do not by themselves establish direct HER2 engagement or pharmacological synergy.

• Sulfo-NHS-LC-Biotin Protocol and QC Guide

  2026-09-16

  Sulfo-NHS-LC-Biotin provides water-compatible, permanent biotin labeling of accessible primary amines on proteins, peptides, and intact cell surfaces. It is suited to surface protein capture and streptavidin-based detection, but not to intracellular labeling or workflows requiring reversible modification.

• Monomethyl auristatin E: State-Aware ADC Assays

  2026-09-16

  Monomethyl auristatin E (MMAE) is a powerful antibody-drug conjugate payload, but its assay value depends on delivery, cell state, and model interpretation. This article develops a state-aware framework linking MMAE mechanism with insights from EBV-driven plasticity in nasopharyngeal carcinoma.

• GSTA1 in α-Amanitin Hepatotoxicity

  2026-09-15

  This study identifies GSTA1 as an unexpected driver of α-amanitin liver injury: its NRF2-associated upregulation accelerates glutathione depletion, reactive oxygen species accumulation, and hepatocyte damage rather than providing protection. The findings place GSTA1 and glutathione metabolism at the center of a mechanistic framework for acute toxin-induced hepatotoxicity and suggest priorities for target validation.

• Tiamulin Workflows for Veterinary Research

  2026-09-15

  Tiamulin combines targeted 50S ribosome inhibition with investigational anti-inflammatory activity, supporting integrated infectious-disease and cytokine-response studies. This practical guide covers stock preparation, MIC testing, cell assays, animal-study planning, resistance analysis, and troubleshooting for reproducible veterinary research.

• Torin2: Selective mTOR Inhibitor Guide

  2026-09-14

  Torin2 is a potent, selective mTOR inhibitor for pathway-focused cancer research. Product information reports nanomolar activity, cellular selectivity over PI3K and other kinases, oral availability, and use in medullary thyroid carcinoma models.

• Chloroquine BA1002 for Reliable Cell Assays

  2026-09-14

  Chloroquine (SKU BA1002) offers a defined research compound for studying lysosomal pH, autophagy, signaling, and cell viability. This scenario-based guide explains concentration selection, solvent compatibility, endpoint interpretation, and vendor-selection criteria for more reproducible biomedical assays.

• Ethacridine Lactate in Chromatin Workflows

  2026-09-13

  A translational perspective on using Ethacridine lactate monohydrate as a qualified contamination-control component while interpreting YAP–TEAD super-enhancer biology in surface ectoderm differentiation.

• Nonivamide: TRPV1 Capsaicin Analog Research

  2026-09-12

  Nonivamide is a Capsaicin analog and selective TRPV1 agonist used to study calcium signaling, cancer cell growth inhibition, and apoptosis. Product information reports activity in glioma and small cell lung cancer models, while recent TRPV1 research provides important context for sensory biology and experimental limits.

• Afatinib (BIBW 2992) in Gastric Cancer Assembloids

  2026-09-11

  Afatinib (BIBW 2992) turns patient-derived gastric cancer assembloids into a practical system for comparing epithelial and stromal drug responses. Its irreversible ErbB-family inhibition supports pathway validation, washout experiments, and resistance-focused targeted therapy research beyond conventional tumor organoids.

• Afatinib (BIBW 2992) in Tumor–Stroma Research

  2026-09-11

  Afatinib and BIBW 2992 provide a mechanistically defined way to interrogate ErbB signaling in patient-derived gastric cancer assembloids, revealing how stromal context reshapes response and translational strategy.

• GS-441524 Workflows for Prodrug Conversion Studies

  2026-09-10

  Build reproducible GS-441524 antiviral research workflows by combining controlled DMSO handling with LC–MS/MS tracking across gastric, blood, and liver matrices. The approach distinguishes parent compound exposure from GS-441524 prodrug conversion, helping researchers interpret bioavailability and pharmacokinetic behavior without conflating chemical stability with antiviral activity.

• Fulvestrant: From ER Degradation to Translation

  2026-09-10

  Fulvestrant (ICI 182,780) offers translational researchers more than a way to inhibit estrogen signaling: it is a mechanistic probe for ERα depletion, MDM2 protein degradation, chemotherapy sensitization, and endocrine therapy resistance research. This article connects breast cancer pharmacology with evidence from an estrogen–endoplasmic reticulum stress model while separating established findings from exploratory opportunities.

• Proximity Labeling Tracks Endogenous Synaptic Trafficking

  2026-09-09

  Pascual-Caro and de Juan-Sanz developed a synaptic-cleft proximity-labeling strategy to monitor activity-dependent exposure of endogenous synaptic proteins without tagging each protein of interest. By shortening the biotinylation window to match synaptic-vesicle exocytosis, the method captured transient surface exposure and provided evidence that ATG9A and NPTX1 traffic to the synaptic surface during neuronal activity.

• Nebivolol hydrochloride: β1 Signaling Workflow

  2026-09-09

  Nebivolol hydrochloride provides a practical, highly selective way to interrogate β1-adrenergic receptor signaling in cardiovascular models. Its defined DMSO formulation and negative result in a sensitized TOR assay make it useful both as a β1-adrenoceptor antagonist and as a pathway-specific comparator in mechanistic experiments.

8370 records 2/558 page Previous Next 12345 下5页 Last page